SignatureFD
RAPP icon

SignatureFD’s Rapport Therapeutics RAPP Stock Holding History

SignatureFD’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$6.89K Hold
205
– – ﹤0.01% 2841
2026
Q2 		$8.54K Hold
205
– – ﹤0.01% 2697
2026
Q1 		$6.41K Sell
205
-20
-9% -$563 ﹤0.01% 2680
2025
Q4 		$6.83K Buy
225
+20
+10% +$554 ﹤0.01% 2579
2025
Q3 		$6.09K Hold
205
– – ﹤0.01% 2590
2025
Q2 		$2.33K Buy
205
+68
+50% +$722 ﹤0.01% 2824
2025
Q1 		$1.37K Buy
+137
New +$1.78K ﹤0.01% 2976

Other funds holding RAPP

Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Sigma Planning Corp
Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Catalyst Private Wealth
Catalyst Private Wealth San Mateo, California $239M AUM 21.76% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

SignatureFD's RAPP Position: Q3 2026 in Review

SignatureFD held its Rapport Therapeutics (RAPP) position steady in Q3 2026 at 205 shares worth $6.89K. The position accounts for ﹤0.01% of the portfolio, ranked #2841.

SignatureFD first reported a position in RAPP in Q1 2025 and has held it in 7 quarters since. The position peaked at $8.54K in Q2 2026. 33 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

  • SignatureFD held 205 shares of Rapport Therapeutics worth $6.89K as of Q3 2026.
  • SignatureFD left its Rapport Therapeutics share count unchanged in Q3 2026.
  • Rapport Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q3 2026, its #2841 holding.
  • SignatureFD first reported a position in Rapport Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • SignatureFD's Rapport Therapeutics position peaked at $8.54K in Q2 2026.
  • 33 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on SignatureFD's 13F filing for Q3 2026, filed 23 Oct 2026.